按药物类型、技术和治疗领域分類的药物研发市场—2025-2032 年全球预测

预计到 2032 年，药物研发市场规模将成长至 2,098.7 亿美元，复合年增长率为 14.48%。

主要市场统计数据
基准年2024年	711.2亿美元
预计2025年	811.1亿美元
预测年份：2032年	2098.7亿美元
复合年增长率（%）	14.48%

透过摘要技术驱动因素、监管压力和影响创新的策略重点，为下一代治疗和药物发现平台奠定基础

随着生物学、工程学和资料科学的融合，药物研发领域持续加速发展，创造出从假设到先导分子的新途径。分析自动化、计算化学和多组体学分析的进步正在缩短药物研发时间，而法律规范和付款人的期望则推动转化价值的更早展现。在此背景下，从试剂采购到后期转化验证，公司必须应对科学机会与营运摩擦之间的复杂相互作用。

事实上，这种环境有利于严谨的投资组合管理和跨职能协作。转化研究团队、外部创新合作伙伴和生产团队必须围绕明确的「可行/不可行」标准和降低风险的里程碑达成一致，以确保投资专注于具有差异化生物学特性和合理开发路径的候选化合物。此外，平台技术和资料互通性的重要性日益提升，使得数位化准备和分析能力与湿实验室实力一样具有战略意义。当相关人员考虑如何配置资本和人才时，他们应该兼顾短期可行性和长期平台价值，以确保研发工作能带来永续的竞争优势。

确定变革性的科学、技术和经营模式转变，以重塑药物发现工作流程并加速转化研究成果

几项变革性转变正在重塑药物研发的营运和策略格局。首先，高内涵资料流与机器学习的整合，使得假设生成和候选药物筛选达到了前所未有的规模，将重点从偶然发现转向资料驱动的先导化合物筛选。其次，透过自动化和标准化试剂实现实验室工作流程的模组化，降低了差异性，并使得跨分散站点的实验可重复，从而支援全球协作和快速迭代。

第三，生技药品工程和小分子融合的进步正在拓展可寻址的生物领域，迫使多学科团队重新思考标靶选择和模式策略。第四，监管机构和付款方越来越重视开发早期强有力的转化证据，强调预测性临床前模型和临床相关的生物标记。最后，从技术许可到共同开发联盟等策略伙伴关係关係正在蓬勃发展。总而言之，这些转变要求各机构采用灵活的营运模式，投资可互通的平台，并建立伙伴关係，以加速发现，同时管理技术和商业性风险。

分析2025年美国政策和关税的累积变化及其对供应链、采购和製造策略的连锁反应

2025年，美国实施的政策变化和关税调整，为药物研发实验室使用的试剂、设备和关键零件的采购带来了新的复杂性。关税调整影响了进口实验室用具和某些生化试剂，迫使采购团队重新评估供应商关係、前置作业时间和总到岸成本。为此，许多组织转向了强调双重采购、延长合约期限以及与供应商更紧密合作的筹资策略，以确保优先分配并减少干扰。

在营运方面，进口成本的上升促使一些集团优先考虑国内高价值製造工艺，或与当地供应商协商批量合约。同时，研究机构加快了替代试剂的资格确认和跨联盟试剂共用，以保持实验的连续性。虽然这些调整需要短期投资和流程重新设计，但也促进了长期供应商的发展和更强大的风险管理实践。展望未来，发现研究的领导者应继续关注政策发展，将关税敏感性纳入其采购模式，并维持灵活的采购通讯协定，以因应跨境贸易条件的突然变化。

识别跨药物类型的细分主导机会区，实行技术和治疗领域能够为优先排序和投资决策提供信息

从细分市场观点来看，其对策略、产能投资和伙伴关係设计的影响存在差异。生物製药和小分子药物的开发路径不同，这决定了上游药物发现的优先顺序和下游的生产决策。生物製药通常需要在表达系统和分析表征方面进行大量投资，而小分子药物则更注重药物化学、ADMET分析和可扩展的合成路线。同时，组合化学和高通量筛检加速了化学多样性探索和候选化合物的鑑定。奈米技术和药物基因体学进一步扩展了标靶给药和患者分层的套件，从而能够实现更精准的转化策略。

治疗领域细分也影响科学研究重点和商业性规划。肿瘤学和神经病学需要复杂的转化模型和专业的生物标记策略，而感染疾病和免疫性疾病通常需要快速反应和强大的病原体生物学专业知识。循环系统疾病和消化器官系统病需要长期安全性分析和人群分层考虑。这些细分视角将指导公司如何分配药物研发工作，选择哪些外部合作伙伴来获得特定能力，以及如何平衡内部平台和外包服务的投资，以最大限度地提高科学研究产量和营运韧性。

检验影响全球资源分配、临床试验安排和製造足迹的区域动态和跨境合作模式

区域动态对组织在何处部署能力、进行临床试验和采购组件有重大影响。美洲地区拥有强大的创业投资、专业服务供应商和转化基础设施，支持先导化合物从发现到临床的快速转化。欧洲、中东和非洲拥有深厚的科学专业知识、多样化的法规环境以及对合作研究网络的高度重视，使其对基于联盟的计画和自适应试验设计具有吸引力。亚太地区拥有高生产能力、蓬勃发展的生物技术生态系统和庞大的临床研究患者群体，使其成为扩大生产规模和加快患者招募的策略选择。

由于各地区监管、报销和营运情况各有不同，公司应制定既能反映本地优势又能维持全球一致性的区域策略。实现这一目标的方法包括：使临床开发计画与各地区的监管路径保持一致，建立区域卓越中心以提升核心竞争力，并协调跨境资料管治，在满足司法管辖区合规要求的同时，实现可重复的科学研究。按地区合理分配资产和伙伴关係关係，可以缩短获得洞察的时间，并提高转化研究成果从实验室到临床转化的成功率。

介绍主要公司和创新合作伙伴，以揭示药物发现生态系统中的竞争地位、伙伴关係趋势和能力差距

重点关注企业和合作联盟，可以发现能力集中的领域和仍然存在的差距。一些公司透过结合硬体、化学和数据分析的专有平台实现差异化，从而加速迭代发现週期并提供差异化服务模式。另一些公司则透过策略联盟拓展业务广度，建构涵盖外包研究供应商、学术联盟和合约研究机构的能力组合，从而能够在不承担固定成本负担的情况下获得专业知识。此外，众多技术创新者正逐步推动检测灵敏度、微型化和通量的提升，迫使现有企业重新思考其营运模式和投资重点。

在整个生态系统中，成功的公司透过整合严格的检验路径和临床相关性筛选器，展现出将平台能力转化为转化证据的能力。他们也注重在关键地区的营运自由，同时务实地管理智慧财产权，并利用合作许可来扩展开发能力。对于评估竞争定位的公司而言，一个关键问题是，是投资于专有平台开发，寻求增值合作伙伴关係以填补能力差距，还是采用平衡控制力和灵活性的混合方法。最佳路径取决于投资组合的雄心、风险接受度以及特定治疗领域需要临床检验的速度。

为产业领导者提供实用且具影响力的建议，以简化其开发平臺、降低供应链风险并利用新兴平台技术

产业领导者应采取有意识的措施，将科学研究目标与营运能力结合，同时在不确定的环境中保留选择。首先，透过投资数据标准、模组化自动化和检验的分析技术来增强平台互通性，确保不同实验室和不同设备产生的结果具有可比性和可操作性。其次，制定采购和供应商发展策略，减少对单一来源的依赖，并纳入跨境中断的紧急应变计画。第三，优先考虑早期转化验证，并透过将临床导向的检测方法、患者来源的模型和生物标记开发整合到药物发现工作流程中来限制下游人员流失。

此外，领导者应培养一种组合式的外部化方法：选择性地将核心差异化要素内包，同时将标准化能力外包给高品质的合作伙伴。为了配合这些营运倡议，应投资于融合湿实验室专业知识、资料科学和监管敏锐度的人才项目，并制定奖励以奖励里程碑主导的进度。最后，应推行务实的合作模式，例如有时限的联盟和基于里程碑的合资企业，以便在无需长期资本投入的情况下快速获取相关能力。将这些行动结合起来，将使组织能够将科学潜力转化为永续的产品线和富有韧性的业务。

我们描述了我们用来整合主要研究和次要研究的严格的混合方法研究途径，以确保可复製的见解和策略相关性。

这些洞察背后的研究采用了混合方法，结合了初步访谈、技术文献整合和系统性能力图谱分析。初步研究包括与药物研发科学家、采购主管和监管专家进行结构化对话，以了解营运痛点和策略重点。二级资讯来源包括同行评审出版物、监管指南文件和技术检验报告，以检验技术主张并揭示创新轨迹。数据整合优先考虑可重复性和可追溯性，将具体观察结果与原始资料和专家归因联繫起来。

为确保严谨性，能力评估重点在于成熟度、扩充性和转化相关性，并采用跨技术和跨地区的一致评估框架。敏感度分析考虑了营运风险状况如何随着供应链风险敞口、监管途径和伙伴关係模式的变化而变化。透过与领域专家的最后覆核和迭代评审週期，对评估结果进行了检验，从而为高阶主管和技术领导者提供切实可行的洞察。

创建整合技术、监管和商业性因素的明确观点，为经营团队决策和策略蓝图提供讯息

总而言之，当今的发现时代要求组织既要有科学雄心，又要有严谨的运作纪律。设备开发、计算建模和转化生物学领域的突破创造了前所未有的机会，但它们也面临着供应链脆弱性、不断变化的政策环境以及对早期临床试验日益增长的期望等现实问题。整合互通平台、务实的伙伴关係策略和强大的供应商管理的公司将占据有利地位，能够将发现转化为临床进展和商业性价值。

从洞察到影响力的转变，需要对平台整合、跨学科人才和采购惯例进行有针对性的投资，以减少单点故障的风险。透过将科学严谨性与策略性营运设计结合，领导者可以加速转换路径，保护关键工作流程免受干扰，并保持长期创新。这些优先事项应体现在董事会层面的讨论、研发规划週期和跨职能措施中，以确保药物研发工作保持韧性、专注力，并符合患者和付款人的期望。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 利用人工智慧驱动的分子对接和预测建模工具加速肿瘤学研发管线中的先导药物最适化
• 采用基于 CRISPR 的基因编辑平台进行罕见疾病研究中的体内治疗候选药物筛检
• 实施云原生生物资讯学工作流程，简化药物标靶发现的多组体学资料整合与分析
• 整合器官晶片微生理系统以提高临床前毒性评估的转换准确性
• 引进高通量单细胞定序技术，在复杂的肿瘤微环境中寻找新的药物标靶
• 利用机器学习演算法对錶型药物筛检中的高内涵成像侦测进行即时分析
• 探索基于生成对抗网路的人工智慧驱动的从头药物设计框架，以扩大化学空间的多样性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：以药物类型分類的药物研发市场

• 生物製药
• 小分子药物

第九章 药物研发市场（依技术）

• 生物分析仪器
• 生物晶片
• 生物资讯学
• 组合化学
• 高通量筛检
• 奈米科技
• 药物基因组学

第 10 章：按治疗领域分類的药物研发市场

• 心血管疾病
• 消化器官系统疾病
• 感染疾病及免疫系统疾病
• 神经病学
• 肿瘤学

第十一章 药物研发市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章 药物研发市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十三章 药物研发市场（按国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alacrita Holdings Limited
  • Amgen Inc.
  • Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • Astrazeneca PLC
  • Atomwise, Inc.
  • BenevolentAI
  • Bio-Rad Laboratories, Inc.
  • Merck & Co., Inc.

The Drug Discovery Market is projected to grow by USD 209.87 billion at a CAGR of 14.48% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 71.12 billion
Estimated Year [2025]	USD 81.11 billion
Forecast Year [2032]	USD 209.87 billion
CAGR (%)	14.48%

Setting the stage for next-generation therapeutics and discovery platforms by summarizing technological drivers, regulatory pressures, and strategic priorities shaping innovation

The drug discovery landscape continues to evolve at an accelerated pace as biology, engineering, and data science converge to create new pathways from hypothesis to lead molecule. Advances in assay automation, computational chemistry, and multiomic analytics are compressing discovery timelines while regulatory frameworks and payer expectations are encouraging earlier demonstration of translational value. Against this backdrop, organizations must navigate a complex interplay of scientific opportunity and operational friction that ranges from reagent sourcing to late-stage translational validation.

In practical terms, this environment rewards disciplined portfolio management and cross-functional collaboration. Translational research groups, external innovation partners, and manufacturing teams must align around clear go/no-go criteria and de-risking milestones so that investment is concentrated on candidates with differentiated biology and plausible development pathways. Moreover, the growing importance of platform technologies and data interoperability means that digital readiness and analytic capability are as strategic as wet-lab prowess. As stakeholders evaluate where to deploy capital and talent, they should consider both near-term feasibility and longer-term platform value so that discovery efforts deliver sustainable competitive advantage.

Identifying the transformative scientific, technological, and business model shifts that are rewriting drug discovery workflows and accelerating translational research outcomes

Several transformative shifts are rewriting the operational and strategic contours of drug discovery. First, the integration of high-content data streams with machine learning is enabling hypothesis generation and candidate triage at scales that were previously impractical, shifting emphasis from serendipitous findings toward data-driven lead selection. Second, modularization of laboratory workflows through automation and standardized reagents reduces variability and enables reproducible experiments across distributed sites, which in turn supports global collaboration and faster iteration.

Third, advances in biologics engineering and small molecule convergence are expanding the addressable biological space, prompting cross-disciplinary teams to rethink target selection and modality strategy. Fourth, regulatory and payer expectations increasingly reward robust translational evidence earlier in development, which places a premium on predictive preclinical models and clinically relevant biomarkers. Finally, strategic partnerships-ranging from technology licensing to co-development alliances-are proliferating as organizations seek to combine complementary capabilities rather than build everything in-house. Together, these shifts demand that organizations adopt flexible operating models, invest in interoperable platforms, and cultivate partnerships that accelerate discovery while managing technical and commercial risk.

Analyzing the cumulative policy and tariff changes in the United States during 2025 and their ripple effects across supply chains, sourcing, and manufacturing strategies

Policy changes and tariff adjustments implemented in the United States during 2025 introduced new layers of complexity for sourcing reagents, instruments, and critical components used across discovery laboratories. Tariff adjustments affected imported laboratory equipment and certain biochemical reagents, prompting procurement teams to reassess supplier relationships, lead times, and total landed costs. In response, many organizations have shifted procurement strategies to emphasize dual sourcing, longer contract horizons, and closer collaboration with suppliers to secure priority allocations and mitigate disruption.

Operationally, elevated import costs led some groups to prioritize onshoring for high-value manufacturing steps or to negotiate volume-based agreements with regional suppliers. Concurrently, research organizations accelerated qualification of alternative reagents and reagents sharing across consortia to preserve experimental continuity. While these adjustments required near-term investment and process redesign, they also catalyzed longer-term supplier development and more robust risk management practices. Moving forward, discovery leaders should continue to monitor policy developments, embed tariff sensitivity into sourcing models, and maintain agile procurement protocols that can respond to sudden changes in cross-border trade conditions.

Uncovering segmentation-driven opportunity zones across drug types, enabling technologies, and therapeutic areas to inform prioritization and investment decisions

Segment-level perspective reveals differentiated implications for strategy, capability investment, and partnership design. When considering drug types, the distinct development pathways for Biologic Drugs versus Small Molecule Drugs shape upstream discovery priorities and downstream manufacturing decisions; biologics typically require deeper investment in expression systems and analytical characterization, while small molecules often emphasize medicinal chemistry, ADMET profiling, and scalable synthetic routes. In terms of enabling technologies, organizations can unlock value by targeting platform integration across Bioanalytical Instruments, Biochips, and Bioinformatics to enable high-resolution data capture and decision automation, while Combinatorial Chemistry and High Throughput Screening accelerate chemical diversity exploration and candidate identification. Nanotechnology and Pharmacogenomics further expand the toolkit for targeted delivery and patient stratification, enabling more precise translational strategies.

Therapeutic area segmentation also directs scientific focus and commercial planning. Oncology and Neurology demand complex translational models and specialized biomarker strategies, whereas Infectious & Immune system Diseases often require rapid-response capabilities and robust pathogen biology expertise. Cardiovascular Disease and Digestive System Diseases call for long-term safety profiling and population stratification considerations. These segmentation lenses together inform where firms should allocate discovery effort, which external partners to engage for specific capabilities, and how to stage investments in in-house platforms versus outsourced services to maximize scientific yield and operational resilience.

Examining regional dynamics and cross-border collaboration patterns that influence resource allocation, clinical trial placement, and manufacturing footprints worldwide

Regional dynamics materially influence where organizations locate capabilities, run trials, and source components. In the Americas, there is strong concentration of venture capital, specialist service providers, and translational infrastructure that supports rapid progression from lead discovery to clinic; this concentration encourages close proximity between discovery teams and clinical collaborators. Europe, Middle East & Africa combines deep scientific expertise, diverse regulatory environments, and an emphasis on collaborative research networks, making it attractive for consortium-based programs and adaptive trial designs. Asia-Pacific presents a mix of high-capacity manufacturing, rapidly growing biotech ecosystems, and a large patient population for clinical research, which makes it a strategic choice for scaling manufacturing and accelerating patient recruitment.

Because regulatory, reimbursement, and operational realities differ across these regions, organizations should design regional strategies that reflect local advantages while maintaining global coherence. This can be achieved by aligning clinical development plans to local regulatory pathways, establishing regional centers of excellence for core capabilities, and orchestrating cross-border data governance that enables reproducible science while meeting jurisdictional compliance requirements. Thoughtful regional allocation of assets and partnerships reduces time-to-insight and enhances the probability that translational findings will survive the transition from lab to clinic.

Profiling leading corporate actors and innovation collaborators to reveal competitive positioning, partnership trends, and capability gaps in discovery ecosystems

A focused view of corporate players and collaborative consortia highlights where capabilities concentrate and where gaps remain. Some organizations distinguish themselves through proprietary platforms that combine hardware, chemistry, and data analytics, enabling them to accelerate iterative discovery cycles and offer differentiated service models. Others pursue breadth through strategic alliances, building capability portfolios that include outsourced research providers, academic partnerships, and contract development organizations to access specialized expertise without bearing full fixed-cost burdens. In addition, a cohort of technology innovators is driving step-change improvements in assay sensitivity, miniaturization, and throughput, which forces incumbents to rethink operational models and investment priorities.

Across the ecosystem, successful actors demonstrate an ability to translate platform capability into translational evidence by integrating rigorous validation pathways and clinical relevance filters. They also manage intellectual property pragmatically, focusing on freedom-to-operate in key geographies while leveraging collaborative licensing to expand development capacity. For organizations assessing competitive positioning, the critical questions are whether to invest in unique platform development, pursue accretive partnerships to fill capability gaps, or adopt a hybrid approach that balances control and flexibility. The optimal path depends on portfolio ambitions, risk tolerance, and the pace at which a given therapeutic area requires clinical validation.

Delivering pragmatic, high-impact recommendations for industry leaders to align R&D pipelines, de-risk supply chains, and capitalize on emergent platform technologies

Industry leaders should take deliberate steps to align scientific ambition with operational capability while preserving optionality in an uncertain environment. First, strengthen platform interoperability by investing in data standards, modular automation, and validated analytics so that results generated in different labs or with different instruments remain comparable and actionable. Second, establish procurement and supplier development strategies that reduce single-source dependencies and incorporate contingency planning for cross-border disruptions. Third, prioritize translational validation early by integrating clinically oriented assays, patient-derived models, and biomarker development into discovery workflows to reduce downstream attrition.

In addition, leaders should cultivate a portfolio approach to externalization: selectively insource core differentiators while outsourcing standardized capabilities to high-quality partners. Complementing these operational moves, invest in talent programs that blend wet-lab expertise, data science, and regulatory insight, and align incentives to reward milestone-driven progress. Finally, pursue pragmatic collaboration models-such as time-limited consortia or milestone-based joint ventures-that enable rapid access to capability without long-term capital overhang. Taken together, these actions will help organizations convert scientific promise into sustainable pipelines and resilient operations.

Explaining the rigorous mixed-method research approach used to synthesize primary and secondary intelligence, ensuring reproducible insights and strategic relevance

The research underpinning these insights employed a mixed-methods approach that combined primary interviews, technical literature synthesis, and systematic capability mapping. Primary engagements included structured conversations with discovery scientists, procurement leaders, and regulatory experts to capture operational pain points and strategic priorities. Secondary sources encompassed peer-reviewed publications, regulatory guidance documents, and technology validation reports to verify technical claims and contextualize innovation trajectories. Data synthesis prioritized reproducibility and traceability, linking specific observations to source material and expert attribution.

To ensure rigor, capability assessments applied consistent evaluation frameworks across technologies and geographies, focusing on maturity, scalability, and translational relevance. Sensitivity analyses explored how variations in supply chain exposure, regulatory pathways, and partnership models could alter operational risk profiles. Throughout, findings were validated through cross-checks with domain experts and iterative review cycles, producing a set of insights designed to be actionable for executives and technical leaders alike.

Drawing conclusive perspectives that integrate technological, regulatory, and commercial factors to inform executive decision-making and strategic roadmaps

In conclusion, the current era of discovery demands that organizations be both scientifically ambitious and operationally disciplined. Breakthroughs in instrumentation, computational modeling, and translational biology create unprecedented opportunity, yet they operate within a reality of supply chain fragility, evolving policy landscapes, and heightened expectations for early clinical relevance. Those who integrate interoperable platforms, pragmatic partnership strategies, and robust supplier management will be better positioned to translate discovery into clinical progress and commercial value.

Moving from insight to impact requires targeted investments in platform integration, talent that spans disciplines, and procurement practices that reduce exposure to single points of failure. By marrying scientific rigor with strategic operational design, leaders can accelerate translational pathways, protect critical workflows from disruption, and sustain long-term innovation. These priorities should inform board-level discussions, R&D planning cycles, and cross-functional initiatives to ensure that discovery efforts remain resilient, focused, and aligned with patient and payer expectations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Utilization of AI-driven molecular docking and predictive modeling tools to accelerate lead optimization in oncology pipelines
• 5.2. Adoption of CRISPR-based gene editing platforms for in vivo therapeutic candidate screening in rare disease research
• 5.3. Implementation of cloud-native bioinformatics workflows to streamline multi-omics data integration and analysis for drug target discovery
• 5.4. Integration of organ-on-chip microphysiological systems to improve translational accuracy of preclinical toxicity assessments
• 5.5. Deployment of high-throughput single-cell sequencing technologies to identify novel drug targets in complex tumor microenvironments
• 5.6. Leveraging machine learning algorithms for real-time analysis of high-content imaging assays in phenotypic drug screening
• 5.7. Exploration of AI-driven de novo drug design frameworks using generative adversarial networks to expand chemical space diversity

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Market, by Drug Type

• 8.1. Biologic Drugs
• 8.2. Small Molecule Drugs

9. Drug Discovery Market, by Technology

• 9.1. Bioanalytical Instruments
• 9.2. Biochips
• 9.3. Bioinformatics
• 9.4. Combinatorial Chemistry
• 9.5. High Throughput Screening
• 9.6. Nanotechnology
• 9.7. Pharmacogenomics

10. Drug Discovery Market, by Therapeutic Area

• 10.1. Cardiovascular Disease
• 10.2. Digestive System Diseases
• 10.3. Infectious & Immune system Diseases
• 10.4. Neurology
• 10.5. Oncology

11. Drug Discovery Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Drug Discovery Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Drug Discovery Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Analysis
  • 14.3.1. Abbott Laboratories
  • 14.3.2. Agilent Technologies, Inc.
  • 14.3.3. Alacrita Holdings Limited
  • 14.3.4. Amgen Inc.
  • 14.3.5. Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd.
  • 14.3.6. Astrazeneca PLC
  • 14.3.7. Atomwise, Inc.
  • 14.3.8. BenevolentAI
  • 14.3.9. Bio-Rad Laboratories, Inc.
  • 14.3.10. Merck & Co., Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRUG DISCOVERY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOANALYTICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOCHIPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DRUG DISCOVERY MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COMBINATORIAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DRUG DISCOVERY MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DRUG DISCOVERY MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DRUG DISCOVERY MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DRUG DISCOVERY MARKET SIZE, BY DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DRUG DISCOVERY MARKET SIZE, BY INFECTIOUS & IMMUNE SYSTEM DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DRUG DISCOVERY MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DRUG DISCOVERY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 99. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 105. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 108. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 109. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 110. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 112. NORTH AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 113. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 116. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 117. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 118. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 119. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 120. LATIN AMERICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 121. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 122. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 129. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. EUROPE DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 133. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 135. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 137. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 140. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 141. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 142. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 143. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 144. MIDDLE EAST DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 145. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. AFRICA DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 148. AFRICA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 149. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 150. AFRICA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 151. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 152. AFRICA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 153. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 156. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 157. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 158. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 159. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 160. ASIA-PACIFIC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. ASEAN DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 166. ASEAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 167. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 168. ASEAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 169. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 170. ASEAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 171. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GCC DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 174. GCC DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 175. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 176. GCC DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 177. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 178. GCC DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 179. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 182. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 183. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 184. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 185. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 186. EUROPEAN UNION DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 187. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. BRICS DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 190. BRICS DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 191. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. BRICS DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 193. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 194. BRICS DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 195. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. G7 DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 198. G7 DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 199. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 200. G7 DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 201. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 202. G7 DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 203. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. NATO DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 206. NATO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 207. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 208. NATO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 209. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 210. NATO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 214. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 215. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 217. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 218. UNITED STATES DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 219. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 220. CANADA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 221. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 222. CANADA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 223. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 224. CANADA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 225. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 226. MEXICO DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 227. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 228. MEXICO DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 229. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 230. MEXICO DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 231. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 232. BRAZIL DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 233. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 234. BRAZIL DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 235. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 236. BRAZIL DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 237. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 239. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 241. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 242. UNITED KINGDOM DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 243. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GERMANY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 247. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 249. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 250. FRANCE DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 251. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 252. FRANCE DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 253. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 254. FRANCE DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 255. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 256. RUSSIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 257. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 258. RUSSIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 259. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 260. RUSSIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 261. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 262. ITALY DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 263. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 264. ITALY DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 265. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 266. ITALY DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 267. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 268. SPAIN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 269. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 270. SPAIN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 271. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 272. SPAIN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 273. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 274. CHINA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 275. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. CHINA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 278. CHINA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 279. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 280. INDIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 281. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 282. INDIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 283. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 284. INDIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 285. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 286. JAPAN DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 287. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 288. JAPAN DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 289. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 290. JAPAN DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 291. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 292. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 293. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 294. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 295. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 296. AUSTRALIA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 297. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 298. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
• TABLE 299. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 300. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 301. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 302. SOUTH KOREA DRUG DISCOVERY MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 303. DRUG DISCOVERY MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 304. DRUG DISCOVERY MARKET, FPNV POSITIONING MATRIX, 2024